Key Stats for Bath & Body Works Stock
- Current Price: ~$19 (May 27, 2026)
- Q1 FY2026 Adjusted EPS: $0.32, beat Street estimate of $0.29 by ~10%
- Q1 FY2026 Net Sales: $1.38B, beat Street estimate of $1.36B by 1.3%, down 3.2% YoY
- Q1 FY2026 EBITDA: $212M, beat Street estimate of $205M; EBITDA margin 15.4%
- Q1 FY2026 Free Cash Flow: $195M, up 29.1% YoY
- FY2026 Adjusted EPS Guidance (reaffirmed): $2.40–$2.65
- TIKR Model Price Target: ~$31
- Implied Upside: ~59%
Bath & Body Works Stock Beats on Q1 Earnings as Consumer-First Transformation Gains Early Traction
Bath & Body Works (BBWI) beat both top- and bottom-line Street estimates in Q1 FY2026, delivering adjusted EPS of $0.32 against a $0.29 consensus and net sales of $1.38B ahead of the $1.36B Street estimate, though revenue declined 3.2% year over year.
The beat came despite continued underlying pressure across the business, with the company leaning on cost discipline, SG&A timing benefits, and early product innovation wins to stay ahead of guidance.
The most credible proof point from the quarter was in Soaps and Sanitizers, where new moisturizing and revitalizing hand soap formulas drove double-digit gains in both average unit retail (AUR) and SKU productivity, with the new format excluded from a key promotional event.
Daniel Heaf, Chief Executive Officer, stated on the Q1 FY2026 earnings call that “better product clearly communicated wins,” tying the hand soap performance directly to the consumer-first formula model of stronger ingredients, upgraded packaging, focused marketing, and sharper execution working together.
The International segment provided a secondary tailwind, with net sales of $70M rising 9% year over year and international retail sales up double digits, while off-mall domestic stores outperformed mall locations on both traffic and conversion, reinforcing the fleet repositioning thesis.
The quarter also surfaced a meaningful overhang: Body Care declined mid-teens, driven by an intentional accessories mix shift in the Disney Princesses 2 collaboration and an overly aggressive pullback on the Everyday Luxury fragrance franchise, which management is correcting with 10 new fragrance restocks effective May 2026.
Amazon, launched in February 2026, is delivering double-digit week-over-week growth, attracting a younger and more affluent consumer profile and generating AURs above the company’s own digital channel, with roughly 94 SKUs live representing approximately 7% of the active in-store assortment.
Free cash flow of $195M rose 29.1% year over year, and the company reaffirmed its FY2026 free cash flow guidance of approximately $600M while redeeming $284M in January 2027 notes during the quarter.
Is Bath & Body Works Stock Undervalued in 2026?
TIKR’s base case values Bath & Body Works at approximately $31 by January 2031, implying around 59% total return from the current price of $19.45, or roughly 10% annualized over approximately 5 years.
If the back-half innovation cycle restores unit volume and AUR in Body Care and the full-fleet store navigation update improves conversion starting in July, TIKR’s model produces a mid-case stock price of approximately $38, implying around 95% total return at roughly 8% annualized.
A more conservative outcome, where the transformation extends before revenue inflects, points to a stock price near $32, roughly 65% total return at around 6% annualized.
The upside scenario, where product relevance recovers more fully and Amazon scales as a meaningful consumer acquisition channel, supports a stock price near $43 and roughly 123% total return at around 10% annualized.
How Did Bath & Body Works Perform in Q1 FY2026 Earnings?
Bath & Body Works delivered adjusted EPS of $0.32 in Q1 FY2026, beating the $0.29 Street estimate by approximately 10%.
Net sales reached $1.38B, clearing the $1.36B consensus, while EBITDA of $212M beat the $205M estimate at a 15.4% margin.
The primary driver of the EPS beat was cost discipline: adjusted SG&A dollars were flat year over year and Fuel for Growth savings partially offset top-line deleverage. Management reaffirmed full-year adjusted EPS guidance of $2.40–$2.65 and free cash flow of approximately $600M.
Is Bath & Body Works Stock Undervalued?
TIKR’s base case values Bath & Body Works stock at approximately $31 by January 2031, implying around 59% total return from the current price of $19.45, or roughly 10% annualized.
Free cash flow of $195M in Q1 rose 29% year over year, and the company reaffirmed approximately $600M in FY2026 FCF, providing a durable cash generation floor beneath the transformation.
The key variable is body care recovery: if back-half innovation restores unit volume and AUR in the company’s largest category, the base case is well supported.
Should You Invest in Bath & Body Works, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Bath & Body Works, Inc. stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Bath & Body Works, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze BBWI stock on TIKR for Free →
